• Pulse Biosciences recently reported long-term data from its first-in-human study of the nPulse Vybrance Percutaneous Electrode System, showing sustained benign thyroid nodule volume reduction over 15–22 months with no regrowth, no serious adverse events, and very high patient satisfaction.
• The data highlight nsPFA’s differentiated nonthermal ablation profile, with continued volume reduction over time and no intranodular fibrosis on ultrasound, suggesting potential durability for organ-sparing thyroid treatments.
• We’ll now examine how this early evidence of durable thyroid nodule ablation could influence Pulse Biosciences’ investment narrative and growth prospects.

Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences, you need to believe nsPFA can carve out meaningful thyroid and cardiac niches and eventually support a much larger revenue base despite today’s small sales and heavy losses. The new Vybrance thyroid durability data strengthens the near term catalyst around early commercial adoption, but it does not remove the central risk that broader clinical trials, payer decisions and guideline updates may take longer or prove less favorable than hoped.

The most relevant recent announcement alongside the thyroid data is the resignation of Chief Commercial Officer Kevin Danahy on February 27, 2026. At a time when Pulse is trying to convert encouraging Vybrance thyroid and early cardiac catheter data into real-world procedure growth, this change in commercial leadership adds another variable around execution on its key catalysts, particularly account penetration, reimbursement progress and utilization of installed systems.

Yet investors should also be aware that if commercialization stumbles or payer coverage evolves more slowly than expected, then...

Pulse Biosciences' narrative projects $29.7 million revenue and $3.9 million earnings by 2028. This requires 601.5% yearly revenue growth and about a $78.6 million earnings increase from -$74.7 million today.

Uncover how Pulse Biosciences' forecasts yield a $22.00 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Before this thyroid update, the most optimistic analysts were assuming revenue could reach about US$42.3 million by 2029, which is far more upbeat than the consensus view and leans heavily on faster Vybrance adoption and strong cardiac traction.

Explore 2 other fair value estimates on Pulse Biosciences - why the stock might be worth as much as 21% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 28 elite penny stocks that balance risk and reward.
• We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.